Rr. Townsend et al., Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency, AM J KIDNEY, 36(6), 2000, pp. 1207-1212
The safety of gadolinium (Gd-benzyloxypropionictetra-acetate [BOPTA] dimegl
umine) infusion was evaluated in 32 patients with severe or moderate chroni
c renal failure in a prospective, randomized, double-blind, placebo-control
led study. Renal failure was defined as severe if creatinine clearance was
between 10 and 29 mL/min, and as moderate if creatinine clearance was betwe
en 30 and 60 mL/min. Serum creatinine level and 24-hour urine samples for c
reatinine clearance were followed up serially for 7 days after the administ
ration of either gadolinium (Gd-BOPTA dimeglumine), 0.2 mmol/kg, or a salin
e infusion. No patient experienced a significant change in renal function,
defined as an increase in serum creatinine level greater than 0.5 mg/dL mor
e than baseline, and no patient required hospitalization or dialysis during
the study period. Gadolinium (Gd-BOPTA dimeglumine) appears to be well tol
erated in patients with moderate to severe renal failure. (C) 2000 by the N
ational Kidney Foundation, Inc.